<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079243</url>
  </required_header>
  <id_info>
    <org_study_id>H-21004160</org_study_id>
    <nct_id>NCT05079243</nct_id>
  </id_info>
  <brief_title>Dermal and Subcutaneous Augmentation and Skin Assessment After Fat-, Stem Cell and Scaffold Injections</brief_title>
  <official_title>Examining the Best Solution for Dermal and Subcutaneous Augmentation and Regeneration Using Ex-vivo Expanded Autologous Adipose-derived Stromal Cells, Autologous Fat Tissue and Natural Tissue Scaffolds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemform</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aleris-Hamlet Hospitaler København</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stemform</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the effect of dermal/subcutaneous injection of ASC enriched fat transplant in a&#xD;
      protective natural scaffold, designed to sustain the ASC viability after dermal/subcutaneous&#xD;
      injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study investigates the effect of different concentrations of autologous ex-vivo expanded&#xD;
      adipose-derived stromal cells (ASCs), fat and a natural scaffold for skin rejuvenation and&#xD;
      augmentation. The aim is to better the volume of fat grafts for cosmetic and reconstructive&#xD;
      purposes. Fat is a near ideal filler, as it is biocompatible. However the retention rate of&#xD;
      fat grafts often result in poor outcomes and it is unpredictable. The investigators have set&#xD;
      up an experimental study in which participants with excess abdominal skin is recruited. They&#xD;
      will have injections with 11 different solutions of fat, ACSs, scaffold and dermal CO2 laser&#xD;
      in the abdominal skin. After 3 months biopsies will be taken and after 6 months all of the&#xD;
      treated area will be removed by an cosmetic abdominoplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Triple blinded, randomized, paired study on healthy participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume assessment</measure>
    <time_frame>Baseline, three months, Six months</time_frame>
    <description>CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell count, immunohistochemistry, skin quality</measure>
    <time_frame>Three months, six months</time_frame>
    <description>Cell count, immunohistochemistry, skin quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry</measure>
    <time_frame>Three months, six months</time_frame>
    <description>Immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin thickness</measure>
    <time_frame>Three months, six months</time_frame>
    <description>Skin thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Augmentation</condition>
  <condition>Reconstruction</condition>
  <arm_group>
    <arm_group_label>Scaffold and adipose-derived stromal cell enriched fat grafts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized and paired injections. Each participant will receive all 11 solutions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls samples</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control samples of untreated skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Scaffold and adipose-derived stromal cell enriched fat grafts</intervention_name>
    <description>eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer</description>
    <arm_group_label>Scaffold and adipose-derived stromal cell enriched fat grafts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18-30 kg/m2&#xD;
&#xD;
          -  400 mL of fat (lipoaspirate) available for liposuction in the thighs or back&#xD;
&#xD;
          -  Desire for abdominoplasty&#xD;
&#xD;
          -  Speaks and reads Danish&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Previous major abdominal surgery&#xD;
&#xD;
          -  Previous cancer or predisposition to cancer&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
&#xD;
          -  Known chronic disease associated with metabolic malfunction or poor healing&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Allergy to necessary anaesthesia&#xD;
&#xD;
          -  Intention of significant weight loss or weight gain within the trial period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik P Mamsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>StemMedical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>stig-Frederik T Koelle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>StemMedical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik P Mamsen</last_name>
    <phone>26888488</phone>
    <phone_ext>0045</phone_ext>
    <email>fpm@stemmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stig-Frederik T Koelle, M.D, PhD</last_name>
    <phone>42304979</phone>
    <phone_ext>0045</phone_ext>
    <email>sfk@stemmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aleris Hamlet</name>
      <address>
        <city>Copenhagen</city>
        <state>Søborg</state>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik P Mamsen, MB</last_name>
      <phone>+4526888488</phone>
      <email>fpm@stemmedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>StemMedical</name>
      <address>
        <city>Copenhagen</city>
        <state>Søborg</state>
        <zip>2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik P Mamsen, MB</last_name>
      <phone>+4526888488</phone>
      <email>fpm@stemmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter B Selvig, Cand. Merc.</last_name>
      <phone>+4540891243</phone>
      <email>peter@stemmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stig-Frederik T Kølle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Upon request IPD can be shared with different parties if assessed valid by the primary investigators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

